| Current Price | $19.08 | Mkt Cap | $1.5B |
|---|---|---|---|
| Open | $15.78 | P/E Ratio | 0.00 |
| Prev. Close | $19.08 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $15.22 - $19.25 | Volume | 24,556,309 |
| 52-Wk Range | $4.34 - $19.25 | Avg. Daily Vol. | 9,329,066 |
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers.
| Current Price | $19.08 | Mkt Cap | $1.5B |
|---|---|---|---|
| Open | $15.78 | P/E Ratio | 0.00 |
| Prev. Close | $19.08 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $15.22 - $19.25 | Volume | 24,556,309 |
| 52-Wk Range | $4.34 - $19.25 | Avg. Daily Vol. | 9,329,066 |
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about VERU.
Recs
lemiwinx
(81.22)
Submitted: 7/14/2022 1:39:27 PM :
Start Price:
$15.41
NASDAQ:VERU Score:
+7.72
Their sabizabulin drug has been submitted for emergency authorized use to the FDA. The drug was successful in reducing deaths by over 50% in severe COVID patients. If successful, this drug will save many lives and generate plenty of revenue to complete their research/trials of their oncology treatments which also uses some parts of sabizabulin.
Find the members with the highest scoring picks in VERU.
HDTVBG (72.24) Score: +24.64
The Score Leader is the player with the highest score across all their picks in VERU.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| HDTVBG | 72.24 | 8/11/2022 |
|
3W | $15.98 | +17.58% | +0.93% | +16.66 | 0 Comment | |
| conliskjr | < 20 | 7/12/2022 |
|
3Y | $14.75 | +27.36% | +11.14% | +16.22 | 0 Comment | |
| lemiwinx | 81.22 | 7/14/2022 |
|
5Y | $15.41 | +21.93% | +14.21% | +7.72 | 1 Comment | |
|
naylorj | 66.84 | 7/15/2022 |
|
1Y | $17.47 | +7.59% | +10.94% | -3.36 | 0 Comment |
| Tangoko | < 20 | 8/12/2022 |
|
3M | $16.09 | +16.78% | +1.04% | -15.75 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
